The Circulating Levels Of Antibodies To α-synuclein Monomers, Oligomers, Fibrils,S100B And IL-4in Parkinson’s Disease

Objective:To detect the circulating titers of antibodies to α-synuclein monomers,oligomers,fibrils,S100B and the concentrations of IL-4in Parkinson’s disease,and toinvestigate the causes of those changes in PD as well as the influencing factors of them.Methods:The serum titers of antibodies to α-synuclein monomers,oligomers,fibrils,S100B and the concentrations of IL-4in38PD patients and30healthysubjects with age and sex-matched were measured by Enzyme-Linked ImmunolsorbentAssay(ELISA).The United Parkinson’s Disease Rate Scale Part III Score（UPDRS III）and Modified Hoehn and Yahr Staging Scale (HY) were evaluated in all studied PDpatients. And all PD patients were divided into Several subgroups according to thedifferent gender,age,duration and treatment.Results: The mean serum antibodies to α-synuclein monomers, S100B titers andIL-4levels are significantly highe（rall P＜0.01） and the The mean serum antibodies toα-synuclein fibrils are significantly lower than healthy subjects group(P<0.01).Antibodies to α-synuclein oligomers were not detected in PD and healthy group. allPD patients were divided into three subgroups according to duration：Disease duration＜6years group、6-10years group、＞10years gtoup, disease duration＜6years groupare significantly highe（rall P＜0.01）, disease duration＞10years gtoup are significantlylower（P＜0.001）. Antibodies to α-synuclein monomers,fibrils,S100B and theconcentrations of IL-4were making Correlation Analysis to UPDRS III score and HYStaging Scale. There was a significant negative correlation between antibodies titers andUPDRS III score and HY Staging Scale（all P＜0.001). There was no correlation to thelevels of IL-4.The PD group were also divided into several different subgroupsaccording to different gender,age,duration and treatment status,however,there is nosignificant differences in all subgroups respectively (all P＞0.05).There were moderatepositive correlations found between antibodies to α-synuclein monomers, fibrils, S100B titers and IL-4levels（rs=0.36，P＜0.05;rs=0.39，P＜0.05;rs=0.35，P＜0.05）.Conclusions: The PD group presented with changing of antibodies to α-synuclein monomers, S100B titers and IL-4level suggests that humoral immunity mayimplicate in PD pathogenesis. With the extension of disease duration，the serum titers ofantibodies to α-synuclein monomers,fibrils,S100B were decrease，leading to theincreased severity of disease which suggests that these antibodies may play aneuroprotective effect in PD. There was a moderate positive correlation between thelevels of IL-4and the titers of antibodies to α-synuclein monomers, fibrils, S100B inPD patients’ serum. IL-4as an immune adjuvant in PD immunotherapy may not playrole on its own, but associated with a complex mechanism of the Downstream of IL-4.The titers of antibodies to α-synuclein monomers, fibrils,S100B in PD serum is notrelated to gender, age, treatment status, the levels of IL-4is not related to gender, age,duration and treatment status. The changes of the antibodies and IL-4level in PDpatients’ serum may be caused by PD itself.